Control and blinding: VTS-270-001 was a non-randomized, open-label, single-arm trial with masking recorded as none; the protocol used no control product and no data monitoring committee.
Sample size and population: the protocol anticipated approximately 60 subjects from 30 sites, and no new subjects could enroll after 20 January 2021. The trial enrolled 27 participants (9 treatment-naïve and 18 previously treated through the expanded access program) aged 4 to 43 years. Treatment-naïve participants started at 400 mg, previously treated participants continued at their current stable dosage, and dose increases stopped as of Amendment 2 (21 April 2021).
Missing efficacy collection: under the amended protocol, efficacy assessments (NPC-SS and clinician CGIC) and the EQ-5D-3L were not collected or analyzed, and auditory brainstem responses were not collected as of 20 January 2021.
Analysis: data were summarized with descriptive statistics, with no hypothesis testing and no imputation of missing data.
Early termination: the trial was terminated early when the sponsor determined that the benefit-risk profile of adrabetadex was not favorable, and treatment was allowed to continue up to 20 October 2021. Of 27 participants, 1 treatment-naive and 2 previously treated participants completed; study termination by the sponsor accounted for 2 and 10 participants. After 21 June 2021, continuation required the investigator to assess that the subject was benefiting from treatment.
Sponsor statements: the protocol states that a comprehensive evaluation of all available clinical data “shows no clear evidence of benefit of adrabetadex in the treatment of neurologic symptoms of NPC” and that “the benefit/risk balance is negative.”
Registry limitations and caveats: early termination